Human Medicine:

The Christie Pathology Partnership Begins Offering VENTANA PD-L1 (SP142) Assay as Companion Diagnostic Test in Bladder Cancer Patients

Following NICE approval in December 2018 a companion diagnostic test is required to determine PD-L1 levels in the tumour tissue of cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer prescribed treatment with pembrolizumab (Keytruda) or atezolizumab (Tecentriq).  PD-L1 testing is funded by NHS England as described in 2017/19 National Tariff High Cost Devices.

The Christie Pathology Partnership (CPP) is one of the first reference laboratories to offer the new companion test. The Ventana PD-L1 (SP142) Assay won FDA approval in July 2018 as a companion diagnostic test to select patients for treatment with atezolizumab. The SP142 assay determines PD L1 expression in immune cells, and the agency requires PD-L1 stained tumour-infiltrating immune cells covering greater ≥5% of the tumour area to be eligible for atezolizumab monotherapy.

“We are pleased to add this companion test to our diagnostic testing services which will enable clinical teams to treat patients with urothelial cancers with newer therapeutic options,” said Dr Pedro Oliveira, Consultant Pathologist at The Christie NHSFT.

Roche also announced last week that it had received FDA approval of the PD-L1 (SP142) assay in identifying triple negative breast cancer patient eligible for atezolizumab plus chemotherapy.

Sue Clark, CPP General Manager said “We are also hugely excited by the addition of the assay to our 2019 pipeline. PD-L1 (SP142) testing in triple negative breast cancer is planned as part of an Early Access to Medicines Scheme (EAMS) approved by MHRA and we plan to be one of the first UK reference laboratories to offer this test”.

For more information please contact [email protected]

The Christie Pathology Partnership

The Christie Pathology Partnership (CPP) is unique joint venture between The Christie NHSFT, Europe’s largest single site cancer centre and SYNLAB, Europe’s largest laboratory provider.  CPP is UKAS accredited to ISO15189 standards offering blood sciences including specialist oncology biochemistry and flow cytometry, cytogenetic analysis, fluorescence in-situ hybridization (FISH), immunohistochemistry and stem cell processing. CPP is fully accredited to ISO-15189.

Latest Human Medicine News
SYNLAB launch Faecal Immunochemical Testing (FIT)

23rd July 2019 – SYNLAB have announced the launch of Faecal Immunochemical Testing (FIT), a bowel / colorectal cancer screening test. FIT is a more…

Read More (about 'SYNLAB launch Faecal Immunochemical Testing (FIT)')
Leukaemia patient goes behind the scenes at The Christie Pathology Partnership

As part of National Biomedical Science Day, the Christie Pathology Partnership (CPP), based at The Christie in Manchester, opened its doors and gave a special…

Read More (about 'Leukaemia patient goes behind the scenes at The Christie Pathology Partnership')
Healthcare Science – an insight into working at Pathology First

Matt Jeffery, Operations Manager at Pathology First explains how he achieved his role, how the profession is evolving and what it’s like to lead the…

Read More (about 'Healthcare Science – an insight into working at Pathology First')
Healthcare Science Week – what’s it like being a Biomedical Scientist (BMS) at Europe’s largest cancer centre?

Jamie Wild is a Biomedical Scientist (BMS) at the Christie Pathology Partnership (CPP), one of the UK’s leading reference centres specialising in cancer detection and…

Read More (about 'Healthcare Science Week – what’s it like being a Biomedical Scientist (BMS) at Europe’s largest cancer centre?')